<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499470</url>
  </required_header>
  <id_info>
    <org_study_id>20.478.486.359</org_study_id>
    <nct_id>NCT03499470</nct_id>
  </id_info>
  <brief_title>Structured Discharge and Follow-up Protocol for COPD Patients Receiving LTOT and NIV</brief_title>
  <official_title>The Effectiveness of Structured Discharge and Follow-up Protocol on Readmission Rate in COPD Patients Receiving LTOT and NIV: A Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celal Bayar University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gazi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duzce University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atatürk Chest Diseases and Chest Surgery Training and Research Hospital Pulmonary Rehabilitation and Home Care Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>T.C. ORDU ÜNİVERSİTESİ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turkish Directorate General of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istanbul University Cerrahpaşa Faculty</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Sciences University Diskapi Yildirim Beyazit Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Readmission to hospital is one of the most important problems in chronic obstructive
      pulmonary disease (COPD) patients who developed chronic respiratory failure. Patients
      receiving long-term oxygen therapy (LTOT) and noninvasive ventilation (NIV) constitute the
      most vulnerable group because of the need for comprehensive care. However, because of lack of
      health care support systems in Turkey, many advanced COPD patients are hospitalized due to
      preventable problems such as insufficient knowledge about the therapies, nonadherence to
      therapy and technical issues related to LTOT/NIV equipment. The aim of this multicenter
      randomized trial is to find out whether a structured discharge and follow-up protocol reduce
      the rate of unplanned, COPD-related hospital readmissions over 90 days in patients receiving
      LTOT or NIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned with Turkish Thoracic Society and Global Alliance Against Respiratory
      Disease-Turkey partnership and being carried out 10 centers throughout Turkey. COPD patients
      who are prescribed long-term oxygen therapy for hypoxemic respiratory failure and/or
      noninvasive ventilation for hypercapnic respiratory failure will be included in the study and
      will be randomized to either intervention or control arm. The intervention mainly consists of
      not only education about the disease and medications but also the education of the equipment
      and how to use it to have the best benefit. Control arm patients will receive usual care,
      which consists of basic education of the patient about the therapies. The primary outcome of
      the study is readmission in 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Readmission rate</measure>
    <time_frame>90days</time_frame>
    <description>The rate of unplanned, COPD-related hospital readmissions over 90 days after discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first exacerbation</measure>
    <time_frame>90 days</time_frame>
    <description>Time to first exacerbation after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of exacerbation</measure>
    <time_frame>90 days</time_frame>
    <description>Total COPD exacerbation rate within 90 days after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>Total hospitalization number due to COPD within 90 days after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>90 days</time_frame>
    <description>Compliance to LTOT and NIV therapies will be assessed by duration of use (number of hours per day and number of nights per week) within 90 days after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term survival</measure>
    <time_frame>One year</time_frame>
    <description>One year survival after discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>Noninvasive Ventilation</condition>
  <condition>Long Term Oxygen Therapy</condition>
  <condition>Chronic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.
Actions in structured discharge and follow up protocol:
Patient education for disease severity and medications
Education of family/relatives about medications and types of equipment
Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)
Preparation of home environment for patients needs
Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed
Outpatient control for the first month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control patients will receive usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocol for structured discharge and follow-up</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        COPD patients who developed chronic respiratory failure and are eligible for long-term
        oxygen therapy (LTOT) or noninvasive ventilation (NIV) according to Turkish National Social
        Security regulations

        Definitions:

        COPD: The diagnosis of COPD is made according to GOLD criteria Chronic respiratory failure:
        PaO2&gt;60mmHg at room air and/or PaCO2&gt; 45

        Eligibility for LTOT:

          1. PaO2 ≤ 55 mmHg or SaO2 ≤ 88% under room air

          2. PaO2 value of 55-59 mmHg or SaO2 ≤ 89% and cor pulmonale with hematocrit &gt;55 or p
             pulmonale in ECG or congestive heart failure.

        Eligibility for NIV:

          1. PaCO2≥55 mmHg or

          2. PaCO2 50 to 54 mmHg and nocturnal desaturation ≤ %88 for 5 minutes under 2lt/min nasal
             O2 therapy 3. PaCO2 50 to 54 mmHg and &gt;2 exacerbations within the last year

        Exclusion Criteria:

        1. Patients receiving LTOT or NIV for a different cause 2. Patients who do not give consent
        3. Patients who are unable to be followed up regularly due to reasons such as living far
        from study center, lack of family support, unwillingness or inability to contact regularly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BEGUM ERGAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TUGBA GOKTALAY, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celal Bayar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PINAR ERGUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences University Ataturk Chest Diseases and Chest Surgery Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ALEV GURGUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>METIN AKGUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ataturk University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NURDAN KOKTURK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EZGI OZYILMAZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cukurova University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ASLI DILEKTASLI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uludag University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BIRSEN OCAKLI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ONER BALBAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duzce University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BEGUM ERGAN, MD</last_name>
    <phone>905326327686</phone>
    <email>begumergan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TUGBA GOKTALAY, MD</last_name>
    <phone>905335173069</phone>
    <email>tugbagoktalay@yahoo.con</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>Izmir</city>
        <state>Narlıdere</state>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begum Ergan, MD</last_name>
      <phone>5326327686</phone>
      <email>begumergan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ezgi Ozyilmaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali Durmaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilgun Demirci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nurdan Kokturk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences University Ataturk Chest Diseases and Chest Surgery Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dicle Yılmaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pınar Ergun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uludag University</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asli Dilektasli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ezgi Demirdogen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duzce University</name>
      <address>
        <city>Düzce</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatih Elverisli, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Fuat Aytekin, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Oner Balbay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ataturk University</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elif Ucar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Metin Akgun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birsen Ocaklı, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zuhal Karakurt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emine Aksoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eylem Tuncay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Funda Elmas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sezai Tasbakan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alev Gurgun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tugba Goktalay, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arzu Yorgancıoğlu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Begum Ergan</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>copd</keyword>
  <keyword>exacerbation</keyword>
  <keyword>structured discharge</keyword>
  <keyword>readmission</keyword>
  <keyword>chronic respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

